Clopidogrel or ticagrelor may be safer and more effective than traditional aspirin for secondary prevention, suggests evidence from seven randomized trials.
The injectable agent s indications now include high-risk patients with primary dyslipidemia who are taking statins but who do not have a history of cardiovascular events.
The absolute risk reduction for a secondary endpoint was slight, but it was by almost 20% and significant and so merits further study, researchers say.
The powerful LDL-lowering agents aren t being used to their fullest potential, but giving them early to STEMI patients along with high-intensity statins would help amend that, researchers say.
The new statement invites comparison with the more comprehensive 2018 ACC/AHA-multisociety statin guidelines. A slew of editorials across several journals do just that.